Rishi Sunak to become first person of color to be Britain’s prime minister
Sunak’s rise to the top office is especially significant in a country that has sometimes struggled to grapple with the legacy of its colonialist past.
This archive gathers solutions-journalism stories and milestones from the United Kingdom — covering health, climate, policy, and social progress. Each entry highlights real, reported advances from across England, Scotland, Wales, and Northern Ireland.
Sunak’s rise to the top office is especially significant in a country that has sometimes struggled to grapple with the legacy of its colonialist past.
Psilocybin therapy is making history: Compass Pathways will launch the world’s first Phase 3 trial for treatment-resistant depression by the end of 2022, enrolling nearly 1,000 participants across two pivotal studies. This is the threshold every promising drug must cross to become an approved medicine, and no psychedelic compound has crossed it before. For the roughly 100 million people worldwide whose depression doesn’t respond to standard treatments, the stakes are real — current options are few, often invasive, and inconsistently helpful. A single guided dose, if the evidence holds, could reshape what care looks like. Beyond depression, this moment signals that a long-stigmatized class of medicines is finally being tested with the rigor patients deserve.
Irish company OceanEnergy has signed on to a four-year project to test, validate and commercialize he OE35, billed as the world’s largest capacity floating wave energy device, off the coast of Orkney, Scotland.
The double-blind longitudinal study followed nearly 1,000 patients with Lynch Syndrome, an inherited genetic condition that increases the individual risk of several cancers, for almost 20 years.
The $24 million investment has been completed by U.K.-based Tata Chemicals Europe, one of Europe’s leading producers of sodium carbonate, salt and baking soda, and they expect it to lower their carbon emissions by more than 10%.
Experts are predicting that this new photoimmunotherapy will be the world’s fifth major cancer treatment following surgery, chemotherapy, radiotherapy, and immunotherapy.
The initiative consists of five large-scale projects to boost biodiversity, tackle the climate crisis, and expand public access to nature.
Clerkenwell Health’s opening marks a turning point for psychedelic medicine, moving it from university labs into dedicated commercial infrastructure built to carry promising compounds through late-stage clinical trials. The clinic’s first focus is patients facing terminal diagnoses — a population where conventional treatments often fall short, and where earlier psilocybin studies showed lasting reductions in anxiety and depression after just one or two sessions. By serving multiple drug developers at once, the facility could meaningfully accelerate how quickly different psychedelic compounds reach the people who need them. It’s a signal that this field is ready to scale.
This crime is a huge problem in Northern Ireland, with statistics showing an instance of abuse occurs every 17 minutes in the country.
Protected and endangered species including hedgehogs, birds, bats, and pet cats have been known to sustain injuries in glue traps, many of which are fatal.